vimarsana.com

Page 3 - Peginterferon Lambda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.

Sylvia wheelerLisa kelly croswellProgeroid laminopathiesDavid corySarah mathiesonCompany annualNational institutes of healthEuropean commissionDrug administrationPrnewswire eiger biopharmaceuticals incEiger biopharmaceuticals incAnges incCorporate affairsActive dialoguePotential peginterferon lambdaStudy topline data planned

Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan

/PRNewswire/ Eiger Biopharmaceuticals Inc. ("Eiger", Nasdaq: EIGR) and AnGes Inc. ("AnGes", TYO: 4563) today announced that the companies entered into an.

United statesSylvia wheelerDavid corySarah mathiesonAnges clinical research laboratoriesPrnewswire eiger biopharmaceuticals incEuropean medicines agencyEiger biopharmaceuticals incAnges incCorporate affairsEmergency use authorizationHepatocyte growth factorChronic discogenic lumbar backGenome editing technologiesSecurities litigation reform actPeginterferon lambda

Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan

PALO ALTO, Calif. and OSAKA, Japan, May 10, 2022 /PRNewswire/ Eiger Biopharmaceuticals Inc. and AnGes Inc. today announced that the companies entered into an agreement for the regulatory.

United statesSylvia wheelerDavid corySarah mathiesonAnges clinical research laboratoriesPrnewswire eiger biopharmaceuticals incEuropean medicines agencyEiger biopharmaceuticals incAnges incCorporate affairsEmergency use authorizationHepatocyte growth factorChronic discogenic lumbar backGenome editing technologiesSecurities litigation reform actPeginterferon lambda

Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan

/PRNewswire/ Eiger Biopharmaceuticals Inc. ("Eiger", Nasdaq: EIGR) and AnGes Inc. ("AnGes", TYO: 4563) today announced that the companies entered into an.

United statesSylvia wheelerDavid corySarah mathiesonAnges clinical research laboratoriesPrnewswire eiger biopharmaceuticals incEuropean medicines agencyEiger biopharmaceuticals incAnges incCorporate affairsEmergency use authorizationHepatocyte growth factorChronic discogenic lumbar backGenome editing technologiesSecurities litigation reform actPeginterferon lambda

Eiger BioPharmaceuticals, Inc (EIGR) CEO David Cory on Q1 2022 Results - Earnings Call Transcript

Eiger BioPharmaceuticals, Inc. (NASDAQ:NASDAQ:EIGR) Q1 2022 Earnings Conference Call May 5, 2022 04:30 PM ET Company Participants Sarah Mathieson - Senior Vice President-Corporate Affairs.

Hong kongUnited statesDavid coreyMichael higginsSarah mathiesonRobert hazlettEiger onecareMerck milliporeYigal nochomovitzAshik mubarackAshiq mubarackDavid coryLuke herrmannMaury raycroftColin hislopBrian skorney

vimarsana © 2020. All Rights Reserved.